Osteoporosis — reduced bone density with architectural deterioration increasing fracture risk — affects 10.2 million US adults and contributes to 1.5 million fractures annually. Hip fractures, the most devastating consequence, carry 20–30% 1-year mortality and dramatically impaired function in survivors. Despite effective pharmacological and non-pharmacological interventions, osteoporosis is profoundly underdiagnosed (only 1 in 5 women with a fragility fracture undergoes evaluation and treatment) — a treatment gap the evidence-based provider can directly address.
Screening, Diagnosis, and Risk Stratification
USPSTF screening recommendations: DEXA for all women ≥65 (Grade B); DEXA for postmenopausal women under 65 with FRAX 10-year major osteoporotic fracture risk ≥9.3% (equivalent to a 65-year-old white woman's risk). Men: no USPSTF recommendation, but screening appropriate for men ≥70 or men ≥50 with fragility fracture, prolonged glucocorticoid use, hypogonadism, or other major risk factors. FRAX (Fracture Risk Assessment Tool): WHO-derived 10-year fracture risk calculator using clinical risk factors with or without DEXA T-score. Treatment threshold: FRAX 10-year hip fracture risk ≥3% OR major osteoporotic fracture risk ≥20% — below these thresholds, pharmacological treatment NNT is generally too high. Important limitation: FRAX underestimates risk in patients with multiple falls, previous high-energy fractures, or chronic glucocorticoid use ≥7.5mg prednisone equivalent daily.
Pharmacotherapy: Comparative Evidence
Bisphosphonates (alendronate, risedronate, zoledronic acid): first-line therapy, most evidence. Vertebral fracture reduction RR ~50%; hip fracture RR ~40% with alendronate and zoledronic acid. Zoledronic acid annual IV infusion increases adherence over daily oral dosing significantly. Denosumab (Prolia, RANK-L inhibitor): subcutaneous injection every 6 months. FREEDOM trial: 68% vertebral fracture risk reduction, 40% hip fracture risk reduction — superior vertebral fracture efficacy to bisphosphonates. Critical issue: rebound vertebral fractures on discontinuation (severe rebound if stopped without bisphosphonate transition) — requires sequential treatment planning. Romosozumab (Evenity, sclerostin inhibitor): anabolic + anti-resorptive — ARCH trial shows 50% vertebral fracture reduction AND hip fracture reduction superior to alendronate at 12 months. Black box warning: increased cardiovascular events vs. alendronate in the ARCH trial — use with caution in patients with prior MI or stroke. Fall prevention: USPSTF Grade B recommendation for multifactorial fall prevention programs (exercise, medication review, vitamin D if deficient, home hazard modification) in community-dwelling adults ≥65 with fall risk. For clinical settings managing osteoporosis patients, our diagnostic equipment catalog includes bone health monitoring supplies and fall risk assessment tools.
